AAOS Updates Clinical Practice Guideline for the Management of Rotator Cuff Injuries
Updated guideline based on the latest evidence-based recommendations ROSEMONT, Ill., Aug. 28, 2025 /PRNewswire/ — The American Academy…
Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need
Leal Therapeutics is developing first-in-class therapeutics to correct metabolic imbalances in the brain for treatment of high unmet…
Barti Raises $12M Series A to Accelerate AI-Powered EHR for Eye Care
SAN FRANCISCO, Aug. 25, 2025 /PRNewswire/ — Barti Software, a leading AI-powered company that provides innovative electronic health records…
Ultima Genomics and Gene by Gene Partner to Expand Global Access to High-Quality, Low-Cost Sequencing on the UG 100™ Platform
Collaboration Extends Global Reach of High-Performance Genomic Sequencing on the UG 100™ Platform FREMONT, Calif. and HOUSTON, Aug.…
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
Ozempic® is the GLP-1 with the most FDA-approved uses for patients with type 2 diabetes including, improvement of…
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb’s Izalontamab brengitecan (Iza-bren) based on data…
Genome BC Funds Research into the Respiratory Fallout of Wildfires
VANCOUVER, BC, Aug. 6, 2025 /CNW/ – British Columbians know the stark realities of climate change, as wildfires…
EVERSANA Announces Development of End-to-End AI-Powered Life Sciences Marketing Agency Built on Google Cloud Technology
CHICAGO, Aug. 4, 2025 /PRNewswire/ — EVERSANA®, a leading provider of commercialization services to the global life sciences industry,…